Clinical trial · Interventional
Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
Phase IIb Randomized Comparative Study of the Efficacy and Safety of Myo-inositol Versus Placebo in Smokers With Bronchial Dysplasia
NCT00783705CI-TRIAL-00030678completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This randomized phase II trial is studying inositol to see how well it works compared with a placebo in preventing lung cancer in current or former smokers with bronchial dysplasia. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of inositol may prevent lung cancer. It is not yet known whether inositol is more effective than a placebo in preventing lung cancer in smokers with bronchial dysplasia.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Squamous Lung Dysplasia | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| inositol | Drug | — | UNRESOLVED |
| placebo | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm I (inositol)
- description
- Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.
- interventionNames
- Drug: inositol
- type
- EXPERIMENTAL
- label
- Arm II (placebo)
- description
- Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.
- interventionNames
- Other: placebo
Primary outcomes (2)
- measure
- Percentage of Participants With Response Determined by Change in the Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples on Participant-specific Analysis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 45 Years
- Maximum age
- 79 Years
Show eligibility criteria text
Inclusion Criteria:
* Histologically confirmed bronchial dysplasia in ≥ 1 site AND meets one of the following criteria:
* Current or former smoker with ≥ a 30 pack-year smoking history and no history of lung cancer
* Stage 0 or I non-small cell lung cancer (NSCLC) curatively treated by surgery (local ablation or resection), adjuvant chemotherapy, or radiotherapy with a ≥ 30 pack-year smoking history
* At least 6 months since prior surgery, adjuvant chemotherapy, or radiotherapy
* No current evidence of lung cancer by CT scan
* No non-calcified lung nodules ≥ 10 mm diameter on spiral CT scan unless cancer is ruled out by PET/CT scan or by biopsy
* ECOG performance status 0-1
* Hemoglobin normal
* Leukocyte count ≥ 3,000/mm³
* Absolute neutrophil count ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
* Alkaline phosphatase ≤ 1.5 times ULN
* ALT and AST ≤ 1.5 times ULN
* BUN ≤ 1.5 times ULN
* Chloride ≤ 1.5 times ULN
* Total CO\_2 ≤ 1.5 times ULN
* Sodium ≤ 1.5 times ULN
* Calcium ≤ 1.5 times ULN
* Potassium ≤ 1.5 times ULN
* Phosphorus ≤ 1.5 times ULN
* Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 30mL/min
* Fasting blood glucose normal
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No cancer within the past 3 years except stage 0 or I NSCLC, nonmelanomatous skin cancer, localized prostate cancer, carcinoma in situ of the cervix, or superficial bladder cancer that was treated \> 6 months ago
* No concurrent uncontrolled illness including, but not limited to, any of the following:
* Ongoing or active infection
* Symptomatic congestive heart failure
* Unstable angina pectoris
* Cardiac arrhythmia
* Severe chronic obstructive pulmonary disease requiring supplemental oxygen
* Uncontrolled hypertension
* Psychiatric illness or social situation that would limit compliance with study requirements
* No schizophrenia or bipolar disorder
* No diabetes
* No requirement for supplemental oxygen (continuous or intermittent)
* SaO\_2 ≥ 90% on room air
* No history of allergic reactions attributed to inositol
* No history of allergies to any ingredient in the study agent or placebo
* No other concurrent investigational agents
* At least 7 days since prior anticoagulant use (e.g., coumadin or heparin)
* More than 6 months since prior participation in another chemoprevention clinical trial
* No prior pneumonectomy
* No prior solid organ transplantation
* No concurrent lithium, carbamazepine, or valproate
* No concurrent use of other natural health products containing inositolReferences
Publications (0)
Data not yet available
No reference posted for this study.